MedPath

Regadenoson

Generic Name
Regadenoson
Brand Names
Lexiscan, Rapiscan
Drug Type
Small Molecule
Chemical Formula
C15H18N8O5
CAS Number
313348-27-5
Unique Ingredient Identifier
7AXV542LZ4
Background

Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

Indication

Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Regadenoson
First Posted Date
2014-04-16
Last Posted Date
2018-09-19
Lead Sponsor
Timothy M. Bateman
Target Recruit Count
40
Registration Number
NCT02115308
Locations
🇺🇸

Saint Luke's Health System, Kansas City, Missouri, United States

Stress CT Perfusion in Patients With Chest Pain

Not Applicable
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Regadenoson
First Posted Date
2013-10-25
Last Posted Date
2021-02-21
Lead Sponsor
University of Chicago
Target Recruit Count
150
Registration Number
NCT01969916
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

Not Applicable
Completed
Conditions
Coronary Artery Disease
CAD
Interventions
Drug: regadenoson
Drug: Optimark®
Device: Myocardial perfusion MRI
First Posted Date
2013-09-25
Last Posted Date
2018-08-20
Lead Sponsor
Daniel S. Berman
Target Recruit Count
44
Registration Number
NCT01949844
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

Phase 4
Completed
Conditions
Myocardial Blood Flow Reserve
Interventions
Drug: Regadenoson
Radiation: Rubidium-82
First Posted Date
2013-08-09
Last Posted Date
2018-08-16
Lead Sponsor
Timothy M. Bateman, MD
Target Recruit Count
80
Registration Number
NCT01919450
Locations
🇺🇸

Saint Luke's Hospital Imaging Center, Kansas City, Missouri, United States

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Regadenoson
Drug: Placebo
First Posted Date
2013-08-08
Last Posted Date
2013-08-30
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
36
Registration Number
NCT01918995
Locations
🇺🇸

Parexel Early Phase Unit, Baltimore, Maryland, United States

Heart Rate Response to Regadenoson and Sudden Cardiac Death

Not Applicable
Completed
Conditions
Left Ventricular Systolic Dysfunction
Sudden Cardiac Death
Interventions
Drug: regadenoson
First Posted Date
2013-04-29
Last Posted Date
2022-10-18
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
90
Registration Number
NCT01842035
Locations
🇺🇸

UAB, Birmingham, Alabama, United States

Phase Analysis and Obstructive CAD on Rubidium PET

Phase 2
Withdrawn
Conditions
Coronary Artery Disease
Interventions
Drug: Regadenoson
First Posted Date
2013-04-26
Last Posted Date
2014-06-02
Lead Sponsor
Emory University
Registration Number
NCT01840696
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Phase 2
Completed
Conditions
Sickle Cell Anemia
Interventions
Drug: Placebo
Drug: Regadenoson
First Posted Date
2013-02-11
Last Posted Date
2018-02-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
100
Registration Number
NCT01788631
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

🇺🇸

Duke University, Durham, North Carolina, United States

and more 9 locations

Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

Phase 4
Completed
Conditions
Ischemic Heart Disease
Interventions
Drug: Regadenoson
First Posted Date
2013-01-30
Last Posted Date
2018-06-15
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
16
Registration Number
NCT01779869
Locations
🇺🇸

Center for Clinical Imaging Research at Washington University School of Medicine, Saint Louis, Missouri, United States

Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI

Phase 2
Completed
Conditions
Myocardial Ischemia
Interventions
Drug: Regadenoson
Drug: gadofoveset trisodium
First Posted Date
2012-08-01
Last Posted Date
2019-08-28
Lead Sponsor
Northwestern University
Target Recruit Count
20
Registration Number
NCT01655043
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy